|
SHIMIZU Yuko
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Topical naphazoline in the treatment of myasthenic blepharoptosis. |
| Journal | Formal name：Muscle & nerve Abbreviation：Muscle Nerve ISSN code：10974598/0148639X |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 44(1),pp.41-4 |
| Author and coauthor | Nagane Yuriko, Utsugisawa Kimiaki, Suzuki Shigeaki, Masuda Masayuki, Shimizu Yuko, Utsumi Hiroya, Uchiyama Shinichiro, Suzuki Norihiro |
| Publication date | 2011/07 |
| Summary | INTRODUCTION:When treating ocular myasthenia gravis (MG), the risk/benefit profile of corticosteroids is unclear, and acetylcholinesterase inhibitors are not very effective. We examined the efficacy of topical naphazoline in the treatment of myasthenic blepharoptosis.METHODS:Sixty MG patients with blepharoptosis (32 with ocular symptoms only and 28 with mild generalized symptoms) were enrolled in a multicenter open trial of topical naphazoline. The effects were reported by patients via a questionnaire and were also confirmed for each patient at the clinic.RESULTS:Among 70 eyes of 60 patients, 20 eyes (28.6%) of 17 patients (28.3%) exhibited a marked response (full eye opening), and 24 eyes (34.3%) of 20 patients (33.3%) showed a good response (adequate but incomplete eye opening). Topical naphazoline was evaluated as useful in the treatment of myasthenic blepharoptosis by >70% of the patients.CONCLUSIONS:Topical naphazoline was found to be an effective supplementary symptomatic treatment for myasthenic blepharoptosis. |
| DOI | 10.1002/mus.22002 |
| PMID | 21491460 |